Brief: Phasebio Pharmaceuticals Q4 Loss Per Share $0.39
30/03/2020 14:08
March 30 (Reuters) - PhaseBio Pharmaceuticals Inc PHAS.O :
* PHASEBIO REPORTS FOURTH QUARTER AND FULL-YEAR 2019
FINANCIAL
RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS
* Q4 LOSS PER SHARE $0.39
* Q4 EARNINGS PER SHARE ESTIMATE $-0.40 -- REFINITIV IBES
DATA
Source text for Eikon: ID:nGNX68Myh3
Further company coverage: PHAS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PhaseBio Pharmaceuticals
See all newsBrief: Phasebio Pharmaceuticals Says Bankruptcy Court Entered Order Approving 1st Amended Combined Disclosure Statement & Chapter 11 Plan On Final Basis
U.S. RESEARCH ROUNDUP- Entegris, FedEx, Kellogg
U.S. RESEARCH ROUNDUP- Armstrong World Industries, Eli Lilly, Netflix
U.S. STOCKS ON THE MOVE-TransDigm, Vaxcyte, Tricida
PhaseBio Pharma slips on bankruptcy plans